In an effort to evaluate IL-1β as a possible TH17-driving adjuvant, Wüthrich et al. demonstrated that an experimental live attenuated B. dermatiditis vaccine supplemented with IL-1β improves TH17-mediated protection against subsequent infection (200). This evidence concerns the gene IL1B and infection.